Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Menadione

FDA-approved product (tablet, oral), marketed as Menadione.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Menadione
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hemorrhage

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Vitamin k
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA3.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli14.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae4.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Menadione in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Menadione with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA

    NCT02507856 · start 2015-07

    Registered record
    Registry ID
    NCT02507856
    Conditions
    Brain Ischemia With Non-valvular Atrial Fibrillation; Transient Ischemic Attack With Non-valvular Atrial Fibrillation
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-07
    Completion
    2022-04
    Enrolment
    10,044

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBrain Ischemia With Non-valvular Atrial Fibrillation; Transient Ischemic Attack With Non-valvular Atrial Fibrillation
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Real-Life Evidence on Stroke Prevention in SPAF

    NCT02485873 · start 2015-05

    Registered record
    Registry ID
    NCT02485873
    Conditions
    Atrial Fibrillation (Prevention of Stroke)
    Interventions
    Rivaroxaban (Xarelto, BAY59-7939); Vitamin K antagonists
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-05
    Completion
    2015-09
    Enrolment
    8,607

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation (Prevention of Stroke)
    InterventionRivaroxaban (Xarelto, BAY59-7939); Vitamin K antagonists
    PhaseNot recorded
    Registry statusCompleted

  • EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis

    NCT02234843 · start 2014-11-13

    Registered record
    Registry ID
    NCT02234843
    Conditions
    Venous Thromboembolism
    Interventions
    Rivaroxaban (Xarelto, BAY59-7939); Rivaroxaban (Xarelto, BAY59-7939); Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-11-13
    Completion
    2019-01-30
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism
    InterventionRivaroxaban (Xarelto, BAY59-7939); Rivaroxaban (Xarelto, BAY59-7939); Standard of Care
    PhasePhase 3
    Registry statusCompleted

  • Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

    NCT02100228 · start 2014-07-14

    Registered record
    Registry ID
    NCT02100228
    Conditions
    Atrial Fibrillation
    Interventions
    Apixaban; Parenteral heparin and/or oral Vitamin K antagonist
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07-14
    Completion
    2017-02-08
    Enrolment
    1,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionApixaban; Parenteral heparin and/or oral Vitamin K antagonist
    PhasePhase 4
    Registry statusCompleted

  • Reversal Agent Use in Patients Treated With Direct Oral Anticoagulants or Vitamin K Antagonists

    NCT01722786 · start 2014-04

    Registered record
    Registry ID
    NCT01722786
    Conditions
    Severe Bleeding; Urgent Surgery
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-04
    Completion
    2019-07-09
    Enrolment
    272

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Bleeding; Urgent Surgery
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

    NCT02640222 · start 2014-01-01

    Registered record
    Registry ID
    NCT02640222
    Conditions
    Anticoagulation
    Interventions
    VKA; Apixaban; dabigatran; rivaroxaban
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-01-01
    Completion
    2019-12-31
    Enrolment
    321,501

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnticoagulation
    InterventionVKA; Apixaban; dabigatran; rivaroxaban
    PhaseNot recorded
    Registry statusCompleted

  • Oral Rivaroxaban in Children With Venous Thrombosis

    NCT01684423 · start 2013-02-19

    Registered record
    Registry ID
    NCT01684423
    Conditions
    Venous Thrombosis
    Interventions
    Rivaroxaban (Xarelto, BAY59-7939); Active comparator; Rivaroxaban (BAY59-7939) suspension
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-02-19
    Completion
    2016-09-01
    Enrolment
    64

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thrombosis
    InterventionRivaroxaban (Xarelto, BAY59-7939); Active comparator; Rivaroxaban (BAY59-7939) suspension
    PhasePhase 2
    Registry statusCompleted

  • Menadione Topical Lotion in Treating Skin Discomfort and Psychological Distress in Patients With Cancer Receiving Panitumumab, Erlotinib Hydrochloride, or Cetuximab

    NCT01393821 · start 2012-01-23

    Registered record
    Registry ID
    NCT01393821
    Conditions
    Dermatologic Complications; Malignant Neoplasm; Pain
    Interventions
    menadione topical lotion; placebo; questionnaire administration; management of therapy complications
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-01-23
    Completion
    2018-07-14
    Enrolment
    27

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDermatologic Complications; Malignant Neoplasm; Pain
    Interventionmenadione topical lotion; placebo; questionnaire administration; management of therapy complications
    PhaseNot applicable
    Registry statusCompleted

  • Use of Phytonadione to Reduce International Normalized Ratio (INR) Variability in Patients on Long-term Warfarin Therapy

    NCT01474460 · start 2011-09

    Registered record
    Registry ID
    NCT01474460
    Conditions
    Coagulation Delay
    Interventions
    phytonadione
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-09
    Completion
    2015-11
    Enrolment
    370

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoagulation Delay
    Interventionphytonadione
    PhaseNot applicable
    Registry statusCompleted

  • Biocomparison Study

    NCT01638182 · start 2011-03

    Registered record
    Registry ID
    NCT01638182
    Conditions
    Bone Health; Vascular Health
    Interventions
    Placebo; Vitamin K1-capsules; Vitamin K2-capsules
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-03
    Completion
    2011-09
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Health; Vascular Health
    InterventionPlacebo; Vitamin K1-capsules; Vitamin K2-capsules
    PhaseNot applicable
    Registry statusCompleted

  • Pharmacokinetics of Omega-3 Monoglycerides

    NCT04382027 · start 2010-11-11

    Registered record
    Registry ID
    NCT04382027
    Conditions
    Healthy
    Interventions
    Omega-3 + vitamin K2 (monoacylglycerol form); Omega-3 + vitamin K2 (ethyl ester)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-11-11
    Completion
    2020-05-05
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOmega-3 + vitamin K2 (monoacylglycerol form); Omega-3 + vitamin K2 (ethyl ester)
    PhaseNot applicable
    Registry statusCompleted

  • Clinical Validation of a New Algorithm for Computerized Dosing of Vitamin K Antagonist Therapy

    NCT01392040 · start 2010-11

    Registered record
    Registry ID
    NCT01392040
    Conditions
    Anticoagulated Patients
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-11
    Completion
    2013-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnticoagulated Patients
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Long-Term Innohep® Treatment Versus a Vitamin K Antagonist (Warfarin) for the Treatment of Venous Thromboembolism (VTE) in Cancer

    NCT01130025 · start 2010-08

    Registered record
    Registry ID
    NCT01130025
    Conditions
    Venous Thromboembolism
    Interventions
    Warfarin; Innohep®
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-08
    Completion
    2014-05
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism
    InterventionWarfarin; Innohep®
    PhasePhase 3
    Registry statusCompleted

  • Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism

    NCT01164046 · start 2010-08

    Registered record
    Registry ID
    NCT01164046
    Conditions
    Venous Thromboembolism; Neoplasms
    Interventions
    low molecular weight heparin; vitamin K antagonists
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2010-08
    Completion
    2014-07
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism; Neoplasms
    Interventionlow molecular weight heparin; vitamin K antagonists
    PhasePhase 3
    Registry statusTerminated

  • International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage

    NCT00928915 · start 2009-07

    Registered record
    Registry ID
    NCT00928915
    Conditions
    Intracranial Hemorrhages
    Interventions
    Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-07
    Completion
    2015-01
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIntracranial Hemorrhages
    InterventionProthrombin complex concentrate (PCC); fresh frozen plasma (FFP)
    PhasePhase 4
    Registry statusCompleted